AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25063373 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine premedication for endotracheal intubation
Number of subjects: 32
Study 22880545 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention
Number of subjects: 131
Study 20861587 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-bead mixed amphetamine salt (MAS) SPD465
Number of subjects: 0
Study 20861587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18555827 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose almonds (73 +/- 3 g/d)
Number of subjects: 27
Study 18555827 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose almonds
Number of subjects: 27
Study 18555827 — intervention group
Group type: COMPARATOR
Intervention: Low saturated fat whole-wheat muffins (control)
Number of subjects: 27
Study 16139655 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 2143
Study 16139655 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 2143
Study 11976799 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD)
Number of subjects: 91
Study 11976799 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia with Lewy bodies (DLB)
Number of subjects: 91
Study 10430198 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine sphygmomanometric blood pressure recordings
Number of subjects: 121
Study 8699873 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) infusion (1,200 mg)
Number of subjects: 14
Study 8699873 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 14
Study 1969870 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg/day)
Number of subjects: 15
Study 1969870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1969870 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Astemizole and Placebo)
Number of subjects: 15
Study 1969870 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 15
Study 30362375 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin and doxorubicin combination
Number of subjects: 0
Study 30362375 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care chemotherapy (investigator's choice of cyclophosphamide/doxorubicin/vincristine or topotecan)
Number of subjects: 0
Study 27476890 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual information (10-min informational animation)
Number of subjects: 82
Study 27476890 — intervention group
Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 82
Study 25593135 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive medical management therapy (AMM)
Number of subjects: 451
Study 25593135 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty and stenting plus aggressive medical therapy (PTAS)
Number of subjects: 451
Study 23740681 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 24
Study 23740681 — intervention group
Group type: COMPARATOR
Intervention: Control group (C carriers)
Number of subjects: 24
Study 21690475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with 12MP plus tetanus
Number of subjects: 167
Study 21690475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with 12MP plus 6MHP
Number of subjects: 167
Study 21690475 — intervention group
Group type: COMPARATOR
Intervention: CY pretreatment
Number of subjects: 167
Study 21690475 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 167
Study 17531327 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5‐20 mg/day)
Number of subjects: 140
Study 17531327 — intervention group
Group type: COMPARATOR
Intervention: Lithium (600‐1800 mg/day)
Number of subjects: 140
Study 16487090 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band ultraviolet B (NB-UVB) phototherapy + tacalcitol ointment
Number of subjects: 32
Study 16487090 — intervention group
Group type: COMPARATOR
Intervention: Narrow-band ultraviolet B (NB-UVB) phototherapy alone
Number of subjects: 32
Study 14595168 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 44
Study 14595168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10861151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical stimulation of the larynx (L)
Number of subjects: 60
Study 10861151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical stimulation of the trachea-carina (T)
Number of subjects: 60
Study 10861151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical stimulation of the bronchus (B)
Number of subjects: 60
Study 10861151 — intervention group
Group type: COMPARATOR
Intervention: Topical application of 4% lidocaine
Number of subjects: 60
Study 10861151 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lidocaine 1 mg/kg
Number of subjects: 60
Study 9202565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal self-injection therapy
Number of subjects: 50
Study 9202565 — intervention group
Group type: COMPARATOR
Intervention: External vacuum device (Osbon ErecAid system)
Number of subjects: 50
Study 9202565 — intervention group
Group type: EXPERIMENTAL
Intervention: Both modalities
Number of subjects: 50
Study 1528093 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg nalbuphine
Number of subjects: 60
Study 1528093 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg morphine
Number of subjects: 60
Study 1528093 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional opioid)
Number of subjects: 60
Study 2859273 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine 150 mg/day
Number of subjects: 39
Study 2859273 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline 150 mg/day
Number of subjects: 39
Study 2859273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 30467711 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 305
Study 30467711 — intervention group
Group type: COMPARATOR
Intervention: Printed educational materials
Number of subjects: 305
Study 28548601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictured individual with known screening status
Number of subjects: 360
Study 28548601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictured individual with unknown screening status
Number of subjects: 360
Study 28548601 — intervention group
Group type: COMPARATOR
Intervention: No screening status information
Number of subjects: 360
Study 26119013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 203
Study 24301133 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial weight loss programme (Weight Watchers)
Number of subjects: 0
Study 24301133 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 0
Study 21186108 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest VO(2 max) tertile achieving 3-4 dietary goals
Number of subjects: 1334
Study 21186108 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest VO(2 max) tertile achieving 1-2 dietary goals
Number of subjects: 1334
Study 21186108 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest VO(2 max) tertile achieving none of the dietary goals
Number of subjects: 1334
Study 21186108 — intervention group
Group type: COMPARATOR
Intervention: Lowest VO(2 max) tertile achieving none of the dietary goals
Number of subjects: 1334
Study 21244763 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CsA 5 mg/kg/day for two consecutive days/week for 24 weeks
Number of subjects: 243
Study 21244763 — intervention group
Group type: COMPARATOR
Intervention: Placebo for two consecutive days/week for 24 weeks
Number of subjects: 243
Study 21244763 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CsA 5 mg/kg/day
Number of subjects: 243
Study 21244763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 17054446 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled telephone calls from a pediatric diabetes educator (bimonthly 15-30 min for 7 months)
Number of subjects: 123
Study 17054446 — intervention group
Group type: COMPARATOR
Intervention: Control group (no scheduled calls)
Number of subjects: 123
Study 12626887 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/d prednisone as an adjunct to antiretroviral therapy
Number of subjects: 24
Study 12626887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10668714 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine 0.05 mg/kg subcutaneously
Number of subjects: 10
Study 10668714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9132322 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen LAT patches (40 mg, replaced every 12 hours)
Number of subjects: 109
Study 9132322 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium tablets (50 mg b.d.)
Number of subjects: 109
Study 8458364 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 16
Study 8458364 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg)
Number of subjects: 16
Study 8458364 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and diltiazem
Number of subjects: 16
Study 8458364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3741714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg twice daily)
Number of subjects: 13
Study 3741714 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily)
Number of subjects: 13
Study 3741714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30765198 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPPS
Number of subjects: 24
Study 30765198 — intervention group
Group type: COMPARATOR
Intervention: PVE
Number of subjects: 24
Study 30765198 — intervention group
Group type: COMPARATOR
Intervention: Control (no recurrence)
Number of subjects: 24
Study 29193016 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly + TCS
Number of subjects: 325
Study 29193016 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks + TCS
Number of subjects: 325
Study 29193016 — intervention group
Group type: COMPARATOR
Intervention: Placebo + TCS
Number of subjects: 325
Study 29193016 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab + TCS
Number of subjects: 325
Study 29193016 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (qw + TCS, q2w + TCS, placebo + TCS)
Number of subjects: 325
Study 26527564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream
Number of subjects: 70
Study 26527564 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 70
Study 25463825 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus infant massage (Massaged Group)
Number of subjects: 0
Study 25463825 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control Group)
Number of subjects: 0
Study 22248038 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 50 mg
Number of subjects: 295
Study 22248038 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg
Number of subjects: 295
Study 22248038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 20650591 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal chiral chromatographic method using LC/MS/MS technology for eszopiclone quantitation
Number of subjects: 0
Study 18946003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutritional supplementation
Number of subjects: 116
Study 18946003 — intervention group
Group type: COMPARATOR
Intervention: Standard nutritional supplementation
Number of subjects: 116
Study 17308383 — intervention group
Group type: EXPERIMENTAL
Intervention: EnSite NavX three-dimensional mapping system
Number of subjects: 83
Study 17308383 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopy-based mapping
Number of subjects: 83
Study 12679737 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine-amifostine-cisplatin (GAP)
Number of subjects: 40
Study 12679737 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine-cisplatin (GP)
Number of subjects: 40
Study 10847237 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 10847237 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study 9112355 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-B2702-derived peptide (7 mg/kg)
Number of subjects: 0
Study 9112355 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 8401617 — intervention group
Group type: EXPERIMENTAL
Intervention: OFL: 400 mg per os (n = 95)
Number of subjects: 191
Study 8401617 — intervention group
Group type: COMPARATOR
Intervention: CTRX: 1 g intramuscularly (n = 96)
Number of subjects: 191
Study 8401617 — intervention group
Group type: EXPERIMENTAL
Intervention: OFL
Number of subjects: 191
Study 8401617 — intervention group
Group type: COMPARATOR
Intervention: CTRX
Number of subjects: 191
Study 2947710 — intervention group
Group type: EXPERIMENTAL
Intervention: Folium Sennae administered orally
Number of subjects: 340
Study 2947710 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional medicine; Cimetidine and Rheum officinale)
Number of subjects: 340
Study 29263227 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous recording during monaural stimulation
Number of subjects: 60
Study 29263227 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous recording during binaural stimulation
Number of subjects: 60
Study 29263227 — intervention group
Group type: COMPARATOR
Intervention: Conventional sequential recording
Number of subjects: 60
Study 27570447 — intervention group
Group type: EXPERIMENTAL
Intervention: Evogliptin, 5 mg od for 7 days (EVO)
Number of subjects: 36
Study 27570447 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin IR, 1,000 mg bid for 7 days (MET)
Number of subjects: 36
Study 27570447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EVO and MET (EVO + MET)
Number of subjects: 36
Study 25457687 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 0
Study 23221655 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Parenting Today (APT) program with telephone counseling (2 hours/session/week for 8 weeks)
Number of subjects: 39
Study 23221655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention details provided)
Number of subjects: 39
Study 20685536 — intervention group
Group type: EXPERIMENTAL
Intervention: Delaire facemask (DFM)
Number of subjects: 34
Study 20685536 — intervention group
Group type: COMPARATOR
Intervention: Grummons facemask (GFM)
Number of subjects: 34
Study 17919608 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral or vaginal estroprogestative contraception
Number of subjects: 24
Study 17919608 — intervention group
Group type: COMPARATOR
Intervention: No contraception (control group)
Number of subjects: 24
Study 15910446 — intervention group
Group type: EXPERIMENTAL
Intervention: Foremilk
Number of subjects: 62
Study 15910446 — intervention group
Group type: EXPERIMENTAL
Intervention: Hindmilk
Number of subjects: 62
Study 15910446 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 62
Study 12544289 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium diet
Number of subjects: 21
Study 10394483 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency transcranial magnetic stimulation (1 Hz) of left temporoparietal cortex
Number of subjects: 3
Study 10394483 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 3
Study 8855809 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (2 ng/kg) + hydrocortisone (3 micrograms/kg.min) for 6 h before LPS injection
Number of subjects: 23
Study 8855809 — intervention group
Group type: COMPARATOR
Intervention: LPS (2 ng/kg) alone
Number of subjects: 23
Study 1825469 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 60
Study 1825469 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 60
Study 6841130 — intervention group
Group type: EXPERIMENTAL
Intervention: Special dietary counseling and supplements of Sustagen or Isocal
Number of subjects: 97
Study 6841130 — intervention group
Group type: COMPARATOR
Intervention: No special advice or supplements (Control)
Number of subjects: 97
Study 31281046 — intervention group
Group type: COMPARATOR
Intervention: Clinician reporting of angina freedom at baseline
Number of subjects: 912
Study 31281046 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient reporting of angina freedom at baseline
Number of subjects: 912
Study 31281046 — intervention group
Group type: COMPARATOR
Intervention: Clinician reporting of angina freedom at 12 months
Number of subjects: 912
Study 31281046 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient reporting of angina freedom at 12 months
Number of subjects: 912
Study 31281046 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall agreement in CCS grade reporting
Number of subjects: 912
Study 31281046 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant reporting of angina
Number of subjects: 912
Study 28338459 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended iliac port site incision
Number of subjects: 41
Study 28338459 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel incision
Number of subjects: 41
Study 26744198 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.2%) mouthwash
Number of subjects: 75
Study 26744198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (0.05%) mouthwash
Number of subjects: 75
Study 26744198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mouthwash)
Number of subjects: 75
Study 23916631 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant Events Program (PEP) intervention
Number of subjects: 100
Study 23916631 — intervention group
Group type: COMPARATOR
Intervention: Information-Support (IS) control condition
Number of subjects: 100
Study 21593370 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous compression plate
Number of subjects: 66
Study 21593370 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 66
Study 19620700 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 105
Study 19620700 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 105
Study 16837885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground flaxseed muffins (25 g, 50 mg lignans)
Number of subjects: 99
Study 16837885 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy flour muffins (25 g, 42 mg isoflavones)
Number of subjects: 99
Study 16837885 — intervention group
Group type: COMPARATOR
Intervention: Wheat flour muffins (control)
Number of subjects: 99
Study 15326881 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygraph Aware
Number of subjects: 50
Study 15326881 — intervention group
Group type: COMPARATOR
Intervention: Polygraph Unaware
Number of subjects: 50
Study 10933649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin (500 mg daily for 5 days)
Number of subjects: 439
Study 10933649 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (250 mg every 6 h for 7 days)
Number of subjects: 439
Study 9068309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised budesonide
Number of subjects: 87
Study 9068309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 8360133 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg bd
Number of subjects: 408
Study 8360133 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 500 mg tds
Number of subjects: 408
Study 3530781 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol 50 mg
Number of subjects: 16
Study 3530781 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol 100 mg
Number of subjects: 16
Study 3530781 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol 200 mg
Number of subjects: 16
Study 3530781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30837554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill (COCP) exposure
Number of subjects: 95
Study 30837554 — intervention group
Group type: COMPARATOR
Intervention: Current non-hormonal contraceptive practices (control)
Number of subjects: 95
Study 28209155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 35
Study 28209155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 24249840 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity telemonitoring program (n=40), wore a motion sensor continuously for 18 weeks, received weekly step count goals.
Number of subjects: 80
Study 24249840 — intervention group
Group type: COMPARATOR
Intervention: Standard CR (n=40), wore an unreadable motion sensor for measurement purposes only.
Number of subjects: 80
Study 24249840 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity telemonitoring program (n=40).
Number of subjects: 80
Study 23598060 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT rs4680 mutation group
Number of subjects: 140
Study 23598060 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT rs737865 mutation group
Number of subjects: 140
Study 23598060 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT rs165599 mutation group
Number of subjects: 140
Study 23598060 — intervention group
Group type: COMPARATOR
Intervention: CHRNA7 SNPs
Number of subjects: 140
Study 21365047 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft cellular bone matrix (ACBM)
Number of subjects: 21
Study 21365047 — intervention group
Group type: COMPARATOR
Intervention: Conventional allograft (CA)
Number of subjects: 21
Study 18637070 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon (pegIFN) plus ribavirin (RBV)
Number of subjects: 75
Study 17129376 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Manual self-management educational intervention
Number of subjects: 0
Study 17129376 — intervention group
Group type: COMPARATOR
Intervention: Randomised trial
Number of subjects: 0